Myriad Genetics
MYGN
235 hedge funds and large institutions have $2.14B invested in Myriad Genetics in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 45 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 76
2.59% less ownership
Funds ownership: 107.6% → 105.01% (-2.6%)
10% less funds holding
Funds holding: 262 → 235 (-27)
17% less call options, than puts
Call options by funds: $21.2M | Put options by funds: $25.7M
18% less capital invested
Capital invested by funds: $2.62B → $2.14B (-$479M)
51% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 45
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$29.3M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$18.6M |
| 3 |
BlackRock
New York
|
+$14.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.2M |
| 5 |
Morgan Stanley
New York
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$110M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$15.8M |
| 3 |
D.E. Shaw & Co
New York
|
-$14.8M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$8.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.06M |
MYGN Hedge Fund Activity: Q2 2019 in Review
235 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q2 2019, worth a combined $2.14B — down 18% from $2.62B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of MYGN and 22 opened new positions — a net loss of 23 holders — while 76 trimmed existing stakes and 91 added.
The largest buyer was Millennium Management, adding an estimated $29.3M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $110M sold.
- 235 institutional investors held Myriad Genetics (MYGN) as of Q2 2019, down from 262 in Q1 2019.
- Funds reported $2.14B of Myriad Genetics stock for Q2 2019, down 18% quarter-over-quarter.
- 22 funds opened new Myriad Genetics positions in Q2 2019 and 45 closed out, a net change of -23 holders.
- The largest Myriad Genetics buyer in Q2 2019 was Millennium Management, an estimated $29.3M added.
- The largest Myriad Genetics seller in Q2 2019 was Consonance Capital Management, an estimated $110M sold.
Based on aggregated 13F filings for Q2 2019.